If you are a Healthcare Professional and you would like to log in to access this content, please click "Login".
You are now leaving the Lilly Medical Web site
The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Eli Lilly and Company does not control, influence, or endorse this site, and the opinions, claims or comments expressed on this site should not be attributed to Eli Lilly and Company. Eli Lilly and Company is not responsible for the privacy policy of any third party web sites. We encourage you to read the privacy policy of every web site you visit.
Menu closed
Please use a minimum of three unique search wordsOur search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Humalog ® (insulin lispro)
This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information:
Humalog Summary of Product Characteristics (SmPC)
Humalog® (insulin lispro): Changing from other mealtime insulin products
Dose adjustment may be needed when transitioning from another insulin to insulin lispro.
Detailed
Information
Dose
adjustment may be needed when transitioning from another insulin to
IL-100.1
A
change in dosage of insulin may be needed when there are changes
in
strength
brand
(manufacturer)
type
(regular/soluble, NPH/isophane, etc)
species
(animal, human, human insulin analogue) and/or
method
of manufacture (recombinant DNA versus animal-source insulin).2
For
fast-acting insulins, any patient also on basal insulin must optimise
dosage of both insulins to obtain glucose control across the whole
day, particularly nocturnal/fasting glucose control.2
Transferring
a patient with DM to another type or brand of insulin should be done
under strict medical supervision.2
References
1.
Data on file, Eli Lilly and Company and/or one of its subsidiaries.
2.
Humalog [summary of product characteristics]. Eli Lilly Nederland
B.V., The Netherlands.
Glossary
DM =
diabetes mellitus
GC =
glucose control
IL-100
= Humalog® (insulin lispro) 100 units/mL
Date of Last Review:January 27, 2020
Was this answer helpful to you?
Contact Lilly
Call or Email us
If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at ukmedinfo@lilly.com